-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Claficapavir
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/2055732-24-4.gif)
| Category | Human immunodeficiency Virus (HIV) |
| CAS | 2055732-24-4 |
| Description | Claficapavir, a specific nucleocapsid protein (NC) inhibitor with an IC50 of about 1 μM, strongly binds to HIV-1 NC (Kd = 20 nM) thereby inhibiting the chaperone properties of NC and resulting in good antiviral activity against HIV-1. |
Product Information
| Synonyms | A1752; 3-Thiazolidinepropanoic acid, 5-[[5-(4-chlorophenyl)-2-furanyl]methylene]-4-oxo-2-thioxo-, (5Z)-; (Z)-3-(5-((5-(4-chlorophenyl)furan-2-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl)propanoic acid |
| IUPAC Name | 3-[(5Z)-5-[[5-(4-chlorophenyl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic acid |
| Molecular Weight | 393.86 |
| Molecular Formula | C17H12ClNO4S2 |
| Canonical SMILES | C1=CC(=CC=C1C2=CC=C(O2)C=C3C(=O)N(C(=S)S3)CCC(=O)O)Cl |
| InChI | InChI=1S/C17H12ClNO4S2/c18-11-3-1-10(2-4-11)13-6-5-12(23-13)9-14-16(22)19(17(24)25-14)8-7-15(20)21/h1-6,9H,7-8H2,(H,20,21)/b14-9- |
| InChIKey | YZLFZFALAZYTCI-ZROIWOOFSA-N |
| Boiling Point | 594.9±60.0°C at 760 mmHg |
| Purity | >98% (HPLC) |
| Density | 1.6±0.1 g/cm3 |
| Solubility | 10 mM in DMSO |
| Appearance | Solide Powder |
| Storage | Powder: -20°C 4 months 4°C 6 months In solvent: -80°C 6 months -20°C 1 months |
| Complexity | 589 |
| Exact Mass | 392.9896279 |
| In Vitro | Claficapavir binds directly to HIV-1 NC, thereby inhibiting specific chaperone functions of NC including Psi RNA dimerization and complementary trans-activation response element (cTAR) DNA destabilization, and it also disrupts the proper Gag processing. |
| Target | HIV |
| XLogP3-AA | 3.9 |
